Drug Profile
Research programme: RNA interference-based inflammation therapeutics - Adhera Therapeutics
Alternative Names: MDR-06155Latest Information Update: 17 Apr 2019
Price :
$50
*
At a glance
- Originator Nastech Pharmaceutical Company
- Developer Marina Biotech
- Class Small interfering RNA
- Mechanism of Action Cytokine inhibitors; RNA interference; Tumour necrosis factor inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- Discontinued Inflammatory bowel diseases; Rheumatoid arthritis
Most Recent Events
- 22 Jul 2010 Discontinued - Preclinical for Inflammatory bowel disease in USA (Parenteral)
- 22 Jul 2010 Discontinued - Preclinical for Rheumatoid arthritis in USA (Parenteral)
- 02 Jul 2010 MDRNA merged with Cequent Pharmaceuticals forming Marina Biotech